Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27728268 | 0.89 | SIGMAR1 (0.64) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| SCHEMBL28393 | 0.89 | SIGMAR1 (1.00) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| SCHEMBL894920 | 0.89 | SIGMAR1 (1.00) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| Piperazine SCHEMBL28228981 | 0.87 | SIGMAR1 (0.96) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| SCHEMBL9644712 | 0.87 | SIGMAR1 (0.96) | SIGMAR1HPGDACHEUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1597474 | 0.87 | SIGMAR1 (0.96) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| SCHEMBL17517821 | 0.86 | SIGMAR1 (0.68) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| Piperazine SCHEMBL27760905 | 0.85 | SIGMAR1 (0.93) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| Formic Acid SCHEMBL7986200 | 0.82 | SIGMAR1 (0.86) | SIGMAR1HPGDACHECHRNB2CHRNB4 | |
| SCHEMBL3423662 | 0.82 | SIGMAR1 (0.86) | SIGMAR1HPGDACHEUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102140095-A | Green new process for preparing tizanidine hydrochloride | CHANGZHOU YABANG PHARMACEUTICAL CO LTD | 2011-08-03 | — | — | CN | claimed |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| US-8431540-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2012-09-27 | — | — | US | disclosed |
| US-8026272-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2011-09-27 | — | — | US | disclosed |
| CN-102140095-A | Green new process for preparing tizanidine hydrochloride | CHANGZHOU YABANG PHARMACEUTICAL CO LTD | 2011-08-03 | — | — | CN | disclosed |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S and Wyeth | 2010-09-30 | — | — | US | disclosed |
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | SIGMAR1 3221/4885HPGD 2033/4885ACHE 269/4885 |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | SIGMAR1 3221/4885HPGD 2033/4885ACHE 269/4885 |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | SIGMAR1 3221/4885HPGD 2033/4885ACHE 269/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | SIGMAR1 3221/4885HPGD 2033/4885ACHE 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.